Evotec AG (NASDAQ:EVTCY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

Separately, DZ Bank AG restated a “buy” rating on shares of Evotec AG in a research note on Tuesday, October 25th.

Evotec AG (NASDAQ:EVTCY) opened at 11.07 on Wednesday. The firm’s 50-day moving average price is $0.00 and its 200 day moving average price is $0.00. Evotec AG has a 52-week low of $6.56 and a 52-week high of $11.54.

Evotec AG Company Profile

Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator’s targets and programs.

5 Day Chart for NASDAQ:EVTCY

Receive News & Stock Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related stocks with our FREE daily email newsletter.